Analysis of Relationships between DAT1 Polymorphism Variants, Personality Dimensions, and Anxiety in New Psychoactive Substance (Designer Drug) (NPS) Users
Abstract
:1. Introduction
2. Materials and Methods
2.1. Subjects
2.2. Genotyping
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Council Decision 2005/387/JHA. Official Journal of the European Union.
- European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2020: Key Issues Summary; Publications Office of the European Union: Luxembourg, 2020. [Google Scholar]
- Berger, A.A.; Keefe, J.; Winnick, A.; Gilbert, E.; Eskander, J.P.; Yazdi, C.; Kaye, A.D.; Viswanath, O.; Urits, I. Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia. Best Pr. Res. Clin. Anaesthesiol. 2020, 34, 617–631. [Google Scholar] [CrossRef] [PubMed]
- Andrews, N.J.; Phillips, A.J. Community nurses’ support for patients with fibromyalgia who use cannabis to manage pain. Br. J. Community Nurs. 2021, 26, 92–98. [Google Scholar] [CrossRef]
- Di Trana, A.; Carlier, J.; Berretta, P.; Zaami, S.; Ricci, G. Consequences of COVID-19 lockdown on the misuse and marketing of addictive substances and new psychoactive substances. Front. Psychiatry 2020, 11, 584462. [Google Scholar] [CrossRef] [PubMed]
- Zaami, S.; Marinelli, E.; Varì, M.R. New trends of substance abuse during COVID-19 pandemic: An international perspective. Front. Psychiatry 2020, 11, 700. [Google Scholar] [CrossRef]
- Costa, P.T.; McCrae, R.R. Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory (NEO-FFI) professional manual. Psychol. Assess. Resour. 1992. [Google Scholar]
- Terracciano, A.; Löckenhoff, C.E.; Crum, R.M.; Bienvenu, O.J.; Costa, P.T., Jr. Five-Factor Model personality profiles of drug users. BMC Psychiatry 2008, 8, 22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cohen, K.; Rosenzweig, S.; Rosca, P.; Pinhasov, A.; Weizman, A.; Weinstein, A. Personality Traits and Psychotic Proneness Among Chronic Synthetic Cannabinoid Users. Front. Psychiatry 2020, 11, 355. [Google Scholar] [CrossRef]
- Savulich, G.; Bowden-Jones, O.; Stephenson, R.; Brühl, A.B.; Ersche, K.D.; Robbins, T.W.; Sahakian, B.J. “Hot” and “Cold” cognition in users of club drugs/novel psychoactive substances. Front. Psychiatry 2021, 12, 333. [Google Scholar] [CrossRef] [PubMed]
- Dalkner, N.; Unterrainer, H.-F.; Neubauer, A. Differences in big five personality traits between alcohol and polydrug abus-ers: Implications for treatment in the therapeutic community. Int. J. Ment. Health Addict. 2013, 11, 682–692. [Google Scholar]
- Benotsch, E.G.; Jeffers, A.J.; Snipes, D.J.; Martin, A.M.; Koester, S. The five factor model of personality and the non-medical use of prescription drugs: Associations in a young adult sample. Pers. Individ. Differ. 2013, 55, 852–855. [Google Scholar] [CrossRef]
- Zilberman, N.; Yadid, G.; Efrati, Y.; Neumark, Y.; Rassovsky, Y. Personality profiles of substance and behavioral addic-tions. Addict. Behav. 2018, 82, 174–181. [Google Scholar] [CrossRef]
- Przepiorka, A.; Blachnio, A.; Cudo, A. Relationships between morningness, Big Five personality traits, and problematic Internet use in young adult university students: Mediating role of depression. Chrono Int. 2020, 38, 248–259. [Google Scholar] [CrossRef]
- Ramirez, V.; Wiers, C.E.; Wang, G.; Volkow, N.D. Personality traits in substance use disorders and obesity when compared to healthy controls. Addiction 2020, 115, 2130–2139. [Google Scholar] [CrossRef]
- Zilberman, N.; Yadid, G.; Efrati, Y.; Rassovsky, Y. Who becomes addicted and to what? Psychosocial predictors of sub-stance and behavioral addictive disorders. Psychiatry Res. 2020, 291, 113221. [Google Scholar] [CrossRef]
- Suh, J.J.; Ruffins, S.; Robins, C.E.; Albanese, M.J.; Khantzian, E.J. Self-medication hypothesis: Connecting affective experience and drug choice. Psychoanal. Psychol. 2008, 25, 518–532. [Google Scholar] [CrossRef]
- Mensen, V.T.; Vreeker, A.; Nordgren, J.; Atkinson, A.; de la Torre, R.; Farré, M.; Ramaekers, J.G.; Brunt, T.M. Psychopathological symptoms associated with synthetic cannabinoid use: A comparison with natural cannabis. Psychopharmacology 2019, 236, 2677–2685. [Google Scholar] [CrossRef] [Green Version]
- Pehlivan, S.; Aytac, H.M.; Kurnaz, S.; Pehlivan, M.; Aydin, P.C. Evaluation of COMT (rs4680), CNR2 (rs2501432), CNR2 (rs2229579), UCP2 (rs659366), and IL-17 (rs763780) gene variants in synthetic cannabinoid use disorder patients. J. Addict. Dis. 2020, 38, 495–505. [Google Scholar] [CrossRef] [PubMed]
- Pehlivan, S.; Aytac, H.M.; Aydin, P.C.; Nursal, A.F.; Pehlivan, M. Global and glucocorticoid receptor gene-specific (NR3C1) DNA methylation analysis in patients with cannabinoid or synthetic cannabinoid use disorder. Psychiatry Res. 2021, 298, 113774. [Google Scholar] [CrossRef] [PubMed]
- Oyaci, Y.; Aytac, H.M.; Pasin, O.; Aydin, P.C.; Pehlivan, S. Detection of altered methylation of MB-COMT promotor and DRD2 gene in cannabinoid or synthetic cannabinoid use disorder regarding gene variants and clinical parameters. J. Addict. Dis. 2021, 1–19. [Google Scholar] [CrossRef]
- Koob, G.F. Dopamine, addiction and reward. Semin. Neurosci. 1992, 4, 139–148. [Google Scholar] [CrossRef]
- Di Chiara, G.; Bassareo, V. Reward system and addiction: What dopamine does and doesn’t do. Curr. Opin. Pharmacol. 2007, 7, 69–76. [Google Scholar] [CrossRef]
- Volkow, N.D.; Michaelides, M.; Baler, R. The neuroscience of drug reward and addiction. Physiol. Rev. 2019, 99, 2115–2140. [Google Scholar] [CrossRef]
- Bannon, M.J.; Michelhaugh, S.K.; Wang, J.; Sacchetti, P. The human dopamine transporter gene: Gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur. Neuropsychopharmacol. 2001, 11, 449–455. [Google Scholar] [CrossRef]
- Greenwood, T.; Kelsoe, J.R. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 2003, 82, 511–520. [Google Scholar] [CrossRef]
- Fuke, S.; Suo, S.; Takahashi, N.; Koike, H.; Sasagawa, N.; Ishiura, S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenom. J. 2001, 1, 152–156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hahn, M.K.; Blakely, R.D. Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenom. J. 2002, 2, 217–235. [Google Scholar] [CrossRef] [Green Version]
- Kim, S.J.; Kim, Y.S.; Kim, C.-H.; Lee, H.S. Lack of association between polymorphisms of the dopamine receptor D4 and dopamine transporter genes and personality traits in a Korean population. Yonsei Med. J. 2006, 47, 787–792. [Google Scholar] [CrossRef] [Green Version]
- Kim, S.J.; Kim, Y.S.; Lee, H.S.; Kim, S.Y.; Kim, C.-H. An interaction between the serotonin transporter promoter region and dopamine transporter polymorphisms contributes to harm avoidance and reward dependence traits in normal healthy subjects. J. Neural Transm. 2006, 113, 877–886. [Google Scholar] [CrossRef]
- Chmielowiec, J.; Chmielowiec, K.; Suchanecka, A.; Trybek, G.; Mroczek, B.; Małecka, I.; Grzywacz, A. Associations be-tween the dopamine D4 receptor and DAT1 dopamine transporter genes polymorphisms and personality traits in addicted patients. Int. J. Environ. Res. Public Health 2018, 15, 2076. [Google Scholar] [CrossRef] [Green Version]
- Tzeng, N.-S.; Lu, R.-B.; Yeh, H.-W.; Yeh, Y.-W.; Huang, C.-C.; Yen, C.-H.; Kuo, S.-C.; Chen, C.-Y.; Chang, H.-A.; Ho, P.-S.; et al. The dopamine transporter gene may not contribute to susceptibility and the specific personality traits of amphetamine dependence. Drug Alcohol Depend. 2015, 149, 100–107. [Google Scholar] [CrossRef]
- Van Gestel, S.; Forsgren, T.; Claes, S.; Del Favero, J.; Van Duijn, C.M.; Sluijs, S.; Nilsson, L.-G.; Adolfsson, R.; Van Broeckhoven, C. Epistatic effect of genes from the dopamine and serotonin systems on the temperament traits of Novelty Seeking and Harm Avoidance. Mol. Psychiatry 2002, 7, 448–450. [Google Scholar] [CrossRef] [Green Version]
- Costa, P.; McCrae, R.R. The Revised NEO Personality Inventory (NEO-PI-R); Sage Publications Inc.: Thousand Oaks, CA, USA, 2008; Volume 2, pp. 179–198. [Google Scholar]
- Liechti, M. Novel psychoactive substances (designer drugs): Overview and pharmacology of modulators of monoamine signaling. Swiss. Med. Wkly. 2015, 145, w14043. [Google Scholar] [CrossRef] [PubMed]
- Chmielowiec, K.; Chmielowiec, J.; Masiak, J.; Czekaj, M.; Krawczyk, P.; Soroka, E.; ´Smiarowska, M.; Musiał, W.; Pawłowski, T.; Grzywacz, A. DRD4Exon 3 Gene Polymorphisms in Patients Diagnosed withPolysubstance Use Disorder and Co-Occurrence of a Depressive Episode. Genes 2021, 12, 1834. [Google Scholar] [CrossRef] [PubMed]
- Calboli, F.C.F.; Tozzi, F.; Galwey, N.W.; Antoniades, A.; Mooser, V.; Preisig, M.; Vollenweider, P.; Waterworth, D.; Waeber, G.; Johnson, M.R.; et al. A genome-wide association study of neuroticism in a population-based sample. PLoS ONE 2010, 5, e11504. [Google Scholar] [CrossRef] [Green Version]
- Hettema, J.M.; Prescott, C.A.; Kendler, K.S. Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism. Am. J. Psychiatry 2004, 161, 1581–1587. [Google Scholar] [CrossRef]
- van den Oord, E.J.; Kuo, P.H.; Hartmann, A.M.; Webb, B.T.; Möller, H.J.; Hettema, J.M.; Giegling, I.; Bukszár, J.; Rujescu, D. Genomewide association analysis followed by a rep-lication study implicates a novel candidate gene for neuroticism. Arch. Gen. Psychiatry 2008, 65, 1062–1071. [Google Scholar] [CrossRef] [Green Version]
- Kotov, R.; Gamez, W.; Schmidt, F.; Watson, D. Linking “big” personality traits to anxiety, depressive, and substance use disorders: A meta-analysis. Psychol. Bull. 2010, 136, 768–821. [Google Scholar] [CrossRef] [PubMed]
- Michałowska-Sawczyn, M.; Lachowicz, M.; Grzywacz, A.; Suchanecka, A.; Chmielowiec, J.; Chmielowiec, K.; Chycki, J.; Trybek, G.; Żmijewski, P.; Cięszczyk, P. Analysis of Polymorphic Variants of the Dopamine Transporter (DAT1) Gene Polymorphism and Personality Traits Among Athletes. J. Hum. Kinet. 2020, 72, 79–89. [Google Scholar] [CrossRef] [Green Version]
- Huang, S.-Y.; Chen, H.-K.; Ma, K.-H.; Shy, M.-J.; Chen, J.-H.; Lin, W.-C.; Lu, R.-B. Association of promoter variants of human dopamine transporter gene with schizophrenia in Han Chinese. Schizophr. Res. 2010, 116, 68–74. [Google Scholar] [CrossRef]
- de Azeredo, L.A.; Rovaris, D.L.; Mota, N.R.; Polina, E.R.; Marques, F.Z.; Contini, V.; Vitola, E.S.; Belmonte-de-Abreu, P.; Rohde, L.A.; Grevet, E.H.; et al. Further evidence for the association between a polymorphism in the promoter region of SLC6A3/DAT1 and ADHD: Findings from a sample of adults. Eur. Arch. Psychiatry Clin. Neurosci. 2014, 264, 401–408. [Google Scholar] [CrossRef]
- Vereczkei, A.; Demetrovics, Z.; Szekely, A.; Sarkozy, P.; Antal, P.; Szilagyi, A.; Sasvari-Szekely, M.; Barta, C. Multi-variate analysis of dopaminergic gene variants as risk factors of heroin dependence. PLoS ONE 2013, 8, e66592. [Google Scholar] [CrossRef] [PubMed]
- Kazantseva, A.; Gaysina, D.; Malykh, S.; Khusnutdinova, E. Theroleofdopamine transporter (SLC6A3) and dopamine D2 re-ceptor/ankyrin repeat and kinase domain containing 1 (DRD2/ANKK1) gene polymorphisms in personality traits. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35, 1033–1040. [Google Scholar] [CrossRef]
- Dash, G.F.; Slutske, W.S.; Martin, N.G.; Statham, D.J.; Agrawal, A.; Lynskey, M.T. Big Five personality traits and alcohol, nicotine, cannabis, and gambling disorder comorbidity. Psychol. Addict. Behav. 2019, 33, 420–429. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- DordiNejad, F.G.; Shiran, M.A.G. Personality traits and drug usage among addicts. Lit. Inform. Comput. Educ. J. 2011, 2, 402–405. [Google Scholar] [CrossRef]
- Kuntsche, E.; Knibbe, R.; Gmel, G.; Engels, R. Who drinks and why? A review of socio-demographic, personality, and contextual issues behind the drinking motives in young people. Addict. Behav. 2006, 31, 1844–1857. [Google Scholar] [CrossRef]
- Newcomb, M.D.; Chou, C.-P.; Bentler, P.M.; Huba, G. Cognitive motivations for drug use among adolescents: Longitu-dinal tests of gender differences and predictors of change in drug use. J. Couns. Psychol. 1988, 35, 426. [Google Scholar] [CrossRef]
- Stewart, S.H.; Karp, J.; Pihl, R.O.; Peterson, J. Anxiety sensitivity and self-reported reasons for drug use. J. Subst. Abus. 1997, 9, 223–240. [Google Scholar] [CrossRef]
- Comeau, N.; Stewart, S.H.; Loba, P. The relations of trait anxiety, anxiety sensitivity, and sensation seeking to adolescents’ motivations for alcohol, cigarette, and marijuana use. Addict. Behav. 2001, 26, 803–825. [Google Scholar] [CrossRef]
Hardy–Weinberg Equilibrium Calculator Including Analysis for Ascertainment Bias | Observed (Expected) | Test χ2 | |||
---|---|---|---|---|---|
χ2 | p-Value | ||||
DAT1 NPS users | 9/9 | 2 (2.68) | 9 allele freq = 0.19 10 allele freq = 0.81 | 0.268 | >0.05 |
9/10 | 24 (22.63) | ||||
10/10 | 47 (47.68) | ||||
DAT1 control subjects | 9/9 | 19 (19.19) | 9 allele freq = 0.25 10 allele freq = 0.75 | 0.003 | >0.05 |
9/10 | 114 (113.62) | ||||
10/10 | 168 (168.19) |
Group | DAT1 Genotype Alleles | ||||
---|---|---|---|---|---|
9/9 n (%) | 9/10 n (%) | 10/10 n (%) | 9 n (%) | 10 n (%) | |
NPS users | 2 | 24 | 47 | 28 | 118 |
n = 73 | (0.03) | (0.33) | (0.65) | (0.19) | (0.81) |
Control | 19 | 114 | 168 | 152 | 450 |
n = 301 | (0.06) | (0.39) | (0.56) | (0.25) | (0.75) |
χ2 | 2.48 | 2.37 | |||
p-value | 0.289 | 0.124 |
STAI/NEO Five-Factor Inventory/ | NPS Users (n = 73) | Control (n = 301) | Z | p-Value |
---|---|---|---|---|
STAI state/scale | 6.08 ± 2.23 | 4.69 ± 2.14 | 4.614 | 0.0000 * |
STAI trait/scale | 7.34 ± 2.21 | 5.16 ± 2.18 | 6.889 | 0.0000 * |
Neuroticism/scale | 6.92 ± 2.39 | 4.67 ± 2.01 | 7.160 | 0.0000 * |
Extraversion/scale | 5.78 ± 2.16 | 6.37 ± 1.98 | −2.113 | 0.0345 * |
Openness/scale | 4.84 ± 1.95 | 4.53 ± 1.61 | 1.248 | 0.2118 |
Agreeableness/scale | 4.67 ± 2.06 | 5.60 ± 2.09 | −3.446 | 0.0005 * |
Conscientiousness/scale | 5.82 ± 2.26 | 6.08 ± 2.15 | −0.747 | 0.4550 |
STAI/NEO Five-Factor Inventory | DAT1 | ANOVA | |||||||
---|---|---|---|---|---|---|---|---|---|
NPS Users (n = 73) | Control (n = 301) | 9/9 (n = 21) | 9/10 (n = 138) | 10/10 (n = 215) | Factor | F (p-Value) | ɳ2 | Power (alfa = 0.05) | |
STAI state/scale | 6.08 ± 2.23 | 4.69 ± 2.14 | 4.38 ± 2.25 | 5.05 ± 2.21 | 4.96 ± 2.24 | intercept | F1, 368 = 341.56 (p < 0.0001 *) | 0.481 | 1.000 |
NPS users/control | F1, 368 = 6.30 (p = 0.012 *) | 0.017 | 0.707 | ||||||
DAT1 | F2, 368 = 1.32 (p = 0.267) | 0.007 | 0.285 | ||||||
NPS users/control × DAT1 | F2, 368 = 1.23 (p = 0.291) | 0.007 | 0.269 | ||||||
STAI trait/scale | 7.34 ± 2.21 | 5.16 ± 2.18 | 5.00 ± 2.07 | 5.74 ± 2.36 | 5.54 ± 2.36 | intercept | F1, 368 = 457,68 (p < 0.0001 *) | 0.554 | 1.000 |
NPS users/control | F1, 368 = 15.07 (p = 0.0001 *) | 0.039 | 0.972 | ||||||
DAT1 | F2, 368 = 1.22 (p = 0.295) | 0.007 | 0.266 | ||||||
NPS users/control × DAT1 | F2,368 = 0.39 (p = 0.673) | 0.002 | 0.114 | ||||||
Neuroticism/scale | 6.92 ± 2.39 | 4.67 ± 2.01 | 4.48 ± 2.11 | 5.12 ± 2.36 | 5.16 ± 2.22 | intercept | F1, 368 = 415.23 (p < 0.0001 *) | 0.530 | 1.000 |
NPS users/control | F1, 368 = 14.02 (p = 0.0002 *) | 0.037 | 0.962 | ||||||
DAT1 | F2,36 8 = 2.62 (p = 0.073) | 0.014 | 0.521 | ||||||
NPS users/control × DAT1 | F2, 368 = 4.23 (p = 0.015 *) | 0.022 | 0.739 | ||||||
Extraversion/scale | 5.78 ± 2.16 | 6.37 ± 1.98 | 6.52 ± 2.06 | 6.19 ± 2.04 | 6.33 ± 2.01 | intercept | F1, 368 = 599.92 (p < 0.0001 *) | 0.620 | 1.000 |
NPS users/control | F1, 368 = 0.240 (p = 0.624) | 0.001 | 0.078 | ||||||
DAT1 | F2, 368 = 3.24 (p = 0.040 *) | 0.017 | 0.615 | ||||||
NPS users/control × DAT1 | F2, 368 = 3.81 (p = 0.023 *) | 0.020 | 0.691 | ||||||
Openness/scale | 4.84 ± 1.95 | 4.53 ± 1.61 | 4.29 ± 1.52 | 4.49 ± 1.78 | 4.68 ± 1.63 | intercept | F1, 368 = 409.43 (p < 0.0001 *) | 0.527 | 1.000 |
NPS users/control | F1, 368 = 0.055 (p = 0.814) | 0.0001 | 0.056 | ||||||
DAT1 | F2, 368 = 0.57 (p = 0.564) | 0.003 | 0.145 | ||||||
NPS users/control × DAT1 | F2, 368 = 0.14 (p = 0.872) | 0.001 | 0.071 | ||||||
Agreeableness/scale | 4.67 ± 2.06 | 5.60 ± 2.09 | 4.81 ± 1.63 | 5.30 ± 2.18 | 5.55 ± 2.10 | intercept | F1, 368 = 356,66 (p < 0.0001 *) | 0.492 | 1.000 |
NPS users/control | F1, 368 = 0.24 (p = 0.623) | 0.001 | 0.078 | ||||||
DAT1 | F2, 368 = 0.68 (p = 0.507) | 0.004 | 0.164 | ||||||
NPS users/control × DAT1 | F2, 368 = 1.15 (p = 0.314) | 0.006 | 0.254 | ||||||
Conscientiousness/scale | 5.82 ± 2.26 | 6.08 ± 2.15 | 6.62 ± 2.33 | 6.04 ± 2.10 | 5.96 ± 2.20 | intercept | F1, 368 = 452.91 (p < 0.0001 *) | 0.552 | 1.000 |
NPS users/control | F1, 368 = 0.20 (p = 0.654) | 0.0005 | 0.073 | ||||||
DAT1 | F2, 368 = 0.38 (p = 0.686) | 0.002 | 0.111 | ||||||
NPS users/control × DAT1 | F2, 368 = 0.44 (p = 0.638) | 0.002 | 0.123 |
DAT1 and NEO-FFI Neuroticism Scale | ||||||
---|---|---|---|---|---|---|
{1} M = 7.87 | {2} M = 5.50 | {3} M = 6.49 | {4} M = 4.54 | {5} M = 4.37 | {6} M = 4.78 | |
NPS DAT1 9/10 {1} | 0.1207 | 0.0081 * | 0.0000 * | 0.0000 * | 0.0000 * | |
NPS DAT1 9/9 {2} | 0.5093 | 0.5186 | 0.4636 | 0.6286 | ||
NPS DAT1 10/10 {3} | 0.0000 * | 0.0002 * | 0.0000 * | |||
control DAT1 9/10 {4} | 0.7331 | 0.3373 | ||||
control DAT1 9/9 {5} | 0.4065 | |||||
control DAT1 10/10 {6} | ||||||
DAT1 and NEO-FFI Extraversion Scale | ||||||
{1} M = 5.12 | {2} M = 8.50 | {3} M = 6.23 | {4} M = 6.41 | {5} M = 6.32 | {6} M = 6.35 | |
NPS DAT1 9/10 {1} | 0.0226 | 0.0279 | 0.0044 | 0.0536 | 0.0053 | |
NPS DAT1 9/9 {2} | 0.1179 | 0.1447 | 0.1431 | 0.1322 | ||
NPS DAT1 10/10 {3} | 0.6079 | 0.8807 | 0.7231 | |||
control DAT1 9/10 {4} | 0.8459 | 0.8016 | ||||
control DAT1 9/9 {5} | 0.9418 | |||||
control DAT1 10/10 {6} |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chmielowiec, J.; Chmielowiec, K.; Masiak, J.; Pawłowski, T.; Larysz, D.; Grzywacz, A. Analysis of Relationships between DAT1 Polymorphism Variants, Personality Dimensions, and Anxiety in New Psychoactive Substance (Designer Drug) (NPS) Users. Genes 2021, 12, 1977. https://doi.org/10.3390/genes12121977
Chmielowiec J, Chmielowiec K, Masiak J, Pawłowski T, Larysz D, Grzywacz A. Analysis of Relationships between DAT1 Polymorphism Variants, Personality Dimensions, and Anxiety in New Psychoactive Substance (Designer Drug) (NPS) Users. Genes. 2021; 12(12):1977. https://doi.org/10.3390/genes12121977
Chicago/Turabian StyleChmielowiec, Jolanta, Krzysztof Chmielowiec, Jolanta Masiak, Tomasz Pawłowski, Dariusz Larysz, and Anna Grzywacz. 2021. "Analysis of Relationships between DAT1 Polymorphism Variants, Personality Dimensions, and Anxiety in New Psychoactive Substance (Designer Drug) (NPS) Users" Genes 12, no. 12: 1977. https://doi.org/10.3390/genes12121977